Immunotherapy: Vaccine trials in melanoma -- time for reflection.
The disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.
|Keywords||cancer staging, cancer vaccine, dose response, human, immunology, immunotherapy, interleukin 2, melanoma, metastasis, note, pathology, randomized controlled trial, skin tumor|
|Persistent URL||dx.doi.org/10.1038/nrclinonc.2009.42, hdl.handle.net/1765/16741|
|Journal||Nature Reviews Clinical Oncology|
Eggermont, A.M.M. (2009). Immunotherapy: Vaccine trials in melanoma -- time for reflection. Nature Reviews Clinical Oncology, 6(5), 256–258. doi:10.1038/nrclinonc.2009.42